Wabtec Q3 Adjusted Diluted EPS Rises 22% Year Over Year to $2.83
Bitget2026/10/21 10:33- Wabtec’s third-quarter 2026 adjusted diluted EPS rose 22% year over year to $2.83.
- Net sales climbed 8% year over year to $3.12 billion, driven by growth in Freight and Transit, including acquisitions.
- Adjusted operating margin widened 1.9 percentage points year over year to 22.9%, benefiting from net sales growth and improved gross margins.
- Total backlog increased 23% year over year to $31.44 billion at September 30, 2026.
- The 2026 adjusted EPS guidance range was raised and tightened to $10.85–$11.05.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks
Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.
Crypto prices
More
